Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis

American Journal of Translational Research

Volumn 6, Issue 4, 2014, Pages 340-352

  Ghanem, Ismael ^a   Riveiro, Maria E ^b,c   Paradis, Valerie ^b   Faivre, Sandrine ^b   Vázquez de Parga, Paula M ^d   Raymond, Eric ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b BEAUJON HOSPITAL   (France)

^c Oncology Therapeutic Development   (France)

^d INSERM U773 and Anatomopathology Departments Beaujon University Hospital ^*  (Spain)

Author keywords

Chemokines; CXCL12 chemokine; CXCR4 receptor; CXCR7 receptor; Hepatocellular carcinoma

Indexed keywords

ALX 0651; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR7; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 10; JANUS KINASE 2; MSX 122; PLERIXAFOR; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; ULOCUPLUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER GROWTH; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CHEMOTAXIS; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; T LYMPHOCYTE; UPREGULATION;

EID: 84904574485     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Llovet JM, Burroughs A and Bruix J. Hepatocel-lular carcinoma. Lancet 2003; 362: 1907-1917.
3. Faivre S, Demetri G, Sargent W and Raymond E. Molecular basis for sunitinib effcacy and future clinical development. Nat Rev Drug Discov 2007; 6: 734-745.
4. Furuse J. Sorafenib for the treatment of unre-sectable hepatocellular carcinoma. Biologics 2008; 2: 779-788.
5. Villanueva A, Hernandez-Gea V and Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013; 10: 34-42.
6. Sia D and Villanueva A. Signaling pathways in hepatocellular carcinoma. Oncology 2011; 81 Suppl 1: 18-23.
7. Zlotnik A and Yoshie O. Chemokines: a new classifcation system and their role in immunity. Immunity 2000; 12: 121-127.
8. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348-27357.
9. Baggiolini M. Chemokines and leukocyte traf-fc. Nature 1998; 392: 565-568.
10. Vandercappellen J, Van Damme J and Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008; 267: 226-244.
11. Mehrad B, Keane MP and Strieter RM. Chemokines as mediators of angiogenesis. Thromb Haemost 2007; 97: 755-762.
12. Zhu Q, Han X, Peng J, Qin H and Wang Y. The role of CXC chemokines and their receptors in the progression and treatment of tumors. J Mol Histol 2012; 43: 699-713.
13. Marra F. Chemokines in liver infammation and fbrosis. Front Biosci 2002; 7: d1899-1914.
14. Castello G, Costantini S and Scala S. Targeting the infammation in HCV-associated hepatocel-lular carcinoma: a role in the prevention and treatment. J Transl Med 2010; 8: 109.
15. Larrubia JR, Benito-Martinez S, Calvino M, Sanz-de-Villalobos E and Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 2008; 14: 7149-7159.
16. Kang W and Shin EC. Clinical implications of chemokines in acute and chronic hepatitis C virus infection. Yonsei Med J 2011; 52: 871-878.
17. Liu Y, Poon RT, Feng X, Yu WC, Luk JM and Fan ST. Reduced expression of chemokine receptors on peripheral blood lymphocytes in patients with hepatocellular carcinoma. Am J Gastroenterol 2004; 99: 1111-1121.
18. Roberts LR. Chemokines as attractive targets in liver carcinogenesis. Am J Gastroenterol 2005; 100: 499-501.
19. Huang F and Geng XP. Chemokines and hepa-tocellular carcinoma. World J Gastroenterol 2010; 16: 1832-1836.
20. Fujii H, Itoh Y, Yamaguchi K, Yamauchi N, Ha-rano Y, Nakajima T, Minami M and Okanoue T. Chemokine CCL20 enhances the growth of HuH7 cells via phosphorylation of p44/42 MAPK in vitro. Biochem Biophys Res Commun 2004; 322: 1052-1058.
21. Rubie C, Frick VO, Wagner M, Rau B, Weber C, Kruse B, Kempf K, Tilton B, Konig J and Schilling M. Enhanced expression and clinical sig-nifcance of CC-chemokine MIP-3 alpha in he-patocellular carcinoma. Scand J Immunol 2006; 63: 468-477.
22. Uchida H, Iwashita Y, Sasaki A, Shibata K, Mat-sumoto T, Ohta M and Kitano S. Chemokine receptor CCR6 as a prognostic factor after hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol 2006; 21: 161-168.
23. Ding X, Wang K, Wang H, Zhang G, Liu Y, Yang Q, Chen W and Hu S. High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. J Gastrointest Surg2012; 16: 828-836.
24. Soliman HH, Nagy H, Kotb N and Alm El-Din MA. The role of chemokine CC ligand 20 in patients with liver cirrhosis and hepatocellular carcinoma. Int J Biol Markers 2012; 27: e125-131.
25. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsu-shima K, Yoshida N, Nishikawa S, Kishimoto T and Nagasawa T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393: 591-594.
26. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kiku-tani H and Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635-638.
27. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG and Walenkamp AM. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013; 49: 219-230.
28. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M and Konopleva M. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to ki-nase inhibitors and chemotherapy in AML. Blood 2009; 113: 6215-6224.
29. Aghi M, Cohen KS, Klein RJ, Scadden DT and Chiocca EA. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovas-culature, where microenvironment influences their differentiated phenotypes. Cancer Res 2006; 66: 9054-9064.
30. Mitra P, Shibuta K, Mathai J, Shimoda K, Banner BF, Mori M and Barnard GF. CXCR4 mRNA expression in colon, esophageal and gastric cancers and hepatitis C infected liver. Int J Oncol 1999; 14: 917-925.
31. Wald O, Pappo O, Safadi R, Dagan-Berger M, Beider K, Wald H, Franitza S, Weiss I, Avniel S, Boaz P, Hanna J, Zamir G, Eid A, Mandelboim O, Spengler U, Galun E and Peled A. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol 2004; 34: 1164-1174.
32. Asselah T, Bieche I, Laurendeau I, Paradis V, Vidaud D, Degott C, Martinot M, Bedossa P, Valla D, Vidaud M and Marcellin P. Liver gene expression signature of mild fbrosis in patients with chronic hepatitis C. Gastroenterolo-gy 2005; 129: 2064-2075.
33. Terada R, Yamamoto K, Hakoda T, Shimada N, Okano N, Baba N, Ninomiya Y, Gershwin ME and Shiratori Y. Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-pos-itive cells: implications for inflammatory liver diseases. Lab Invest 2003; 83: 665-672.
34. Hatch HM, Zheng D, Jorgensen ML and Peters-en BE. SDF-1alpha/CXCR4: a mechanism for hepatic oval cell activation and bone marrow stem cell recruitment to the injured liver of rats. Cloning Stem Cells 2002; 4: 339-351.
35. Zheng D, Oh SH, Jung Y and Petersen BE. Oval cell response in 2-acetylaminofuorene/partial hepatectomy rat is attenuated by short interfering RNA targeted to stromal cell-derived fac-tor-1. Am J Pathol 2006; 169: 2066-2074.
36. Mavier P, Martin N, Couchie D, Preaux AM, La-perche Y and Zafrani ES. Expression of stromal cell-derived factor-1 and of its receptor CXCR4 in liver regeneration from oval cells in rat. Am J Pathol 2004; 165: 1969-1977.
37. Tsuchiya A, Imai M, Kamimura H, Takamura M, Yamagiwa S, Sugiyama T, Nomoto M, Heike T, Nagasawa T, Nakahata T and Aoyagi Y. Increased susceptibility to severe chronic liver damage in CXCR4 conditional knock-out mice. Dig Dis Sci 2012; 57: 2892-2900.
38. Hong F, Tuyama A, Lee TF, Loke J, Agarwal R, Cheng X, Garg A, Fiel MI, Schwartz M, Wa-lewski J, Branch A, Schecter AD and Bansal MB. Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1al-pha-mediated stellate cell activation. Hepatol-ogy 2009; 49: 2055-2067.
39. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E and Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
40. Ribatti D, Mangialardi G and Vacca A. Stephen Paget and the 'seed and soil' theory of meta-static dissemination. Clin Exp Med 2006; 6: 145-149.
41. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS and McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-1837.
42. Kaif JT, Yekebas EF, Schurr P, Obonyo D, Wa-chowiak R, Busch P, Heinecke A, Pantel K and Izbicki JR. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005; 97: 1840-1847.
43. Zagzag D, Krishnamachary B, Yee H, Okuyama H, Chiriboga L, Ali MA, Melamed J and Semen-za GL. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005; 65: 6178-6188.
44. Xiang ZL, Zeng ZC, Tang ZY, Fan J, Zhuang PY, Liang Y, Tan YS and He J. Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metasta-ses and poor survival. BMC Cancer 2009; 9: 176.
45. Liu H, Pan Z, Li A, Fu S, Lei Y, Sun H, Wu M and Zhou W. Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol 2008; 5: 373-378.
46. Xiang Z, Zeng Z, Tang Z, Fan J, Sun H, Wu W and Tan Y. Increased expression of vascular endothelial growth factor-C and nuclear CXCR4 in hepatocellular carcinoma is correlated with lymph node metastasis and poor outcome. Cancer J 2009; 15: 519-525.
47. Li W, Gomez E and Zhang Z. Immunohisto-chemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J Exp Clin Cancer Res 2007; 26: 527-533.
48. Lin GT, Tseng HF, Yang CH, Hou MF, Chuang LY, Tai HT, Tai MH, Cheng YH, Wen CH, Liu CS, Huang CJ, Wang CL and Chang HW. Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS 2009; 13: 165-172.
49. Nahon P, Sutton A, Rufat P, Simon C, Trinchet JC, Gattegno L, Beaugrand M and Charnaux N. Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol 2008; 14: 713-719.
50. Nahon P, Sutton A, Rufat P, Faisant C, Simon C, Barget N, Trinchet JC, Beaugrand M, Gattegno L and Charnaux N. Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study. Eur J Gastroenterol Hepa-tol 2007; 19: 425-431.
51. Schimanski CC, Bahre R, Gockel I, Muller A, Fr-erichs K, Horner V, Teufel A, Simiantonaki N, Biesterfeld S, Wehler T, Schuler M, Achenbach T, Junginger T, Galle PR and Moehler M. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer 2006; 95: 210-217.
52. Chetram MA, Don-Salu-Hewage AS and Hinton CV. ROS enhances CXCR4-mediated functions through inactivation of PTEN in prostate cancer cells. Biochem Biophys Res Commun 2011; 410: 195-200.
53. Arora S, Bhardwaj A, Singh S, Srivastava SK, McClellan S, Nirodi CS, Piazza GA, Grizzle WE, Owen LB and Singh AP. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor kap-paB- and hypoxia-inducible factor 1alpha-me-diated up-regulation of CXCR4. J Biol Chem 2013; 288: 21197-21207.
54. Sutton A, Friand V, Brule-Donneger S, Chaigneau T, Ziol M, Sainte-Catherine O, Poire A, Saffar L, Kraemer M, Vassy J, Nahon P, Salz-mann JL, Gattegno L and Charnaux N. Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res 2007; 5: 21-33.
55. Zhang R, Pan X, Huang Z, Weber GF and Zhang G. Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One 2011; 6: e23831.
56. Chu H, Zhou H, Liu Y, Liu X, Hu Y and Zhang J. Functional expression of CXC chemokine re-cepter-4 mediates the secretion of matrix me-talloproteinases from mouse hepatocarcino-ma cell lines with different lymphatic metastasis ability. Int J Biochem Cell Biol 2007; 39: 197-205.
57. Mitra P, De A, Ethier MF, Mimori K, Kodys K, Shibuta K, Mori M, Madison JM, Miller-Grazia-no C and Barnard GF. Loss of chemokine SDF-1alpha-mediated CXCR4 signalling and receptor internalization in human hepatoma cell line HepG2. Cell Signal 2001; 13: 311-319.
58. Kim SW, Kim HY, Song IC, Jin SA, Lee HJ, Yun HJ, Kim S and Jo DY. Cytoplasmic trapping of CXCR4 in hepatocellular carcinoma cell lines. Cancer Res Treat 2008; 40: 53-61.
59. Lin TJ, Liao LY, Lin CL, Shih LS, Chang TA, Tu HY, Chen RC and Wang CS. Spontaneous regression of hepatocellular carcinoma: a case report and literature review. Hepatogastroenter-ology 2004; 51: 579-582.
60. Oquinena S, Inarrairaegui M, Vila JJ, Alegre F, Zozaya JM and Sangro B. Spontaneous regression of hepatocellular carcinoma: three case reports and a categorized review of the literature. Dig Dis Sci 2009; 54: 1147-1153.
61. Shen X, Li N, Li H, Zhang T, Wang F and Li Q. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 136: 1745-1754.
62. Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, Sato Y, Abo T, Hor-witz DA and Aoyagi Y. Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 2006; 45: 254-262.
63. Eferl R. A dual role for interferon gamma signalling in hepatocellular carcinoma. J Hepatol 2012; 57: 940-942.
64. Li P, Du Q, Cao Z, Guo Z, Evankovich J, Yan W, Chang Y, Shao L, Stolz DB, Tsung A and Geller DA. Interferon-gamma induces autophagy with growth inhibition and cell death in human he-patocellular carcinoma (HCC) cells through in-terferon-regulatory factor-1 (IRF-1). Cancer Lett 2012; 314: 213-222.
65. Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen M and Ren H. Gene therapy with CX3CL1/Fractal-kine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther 2007; 14: 1226-1234.
66. Hirano S, Iwashita Y, Sasaki A, Kai S, Ohta M and Kitano S. Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infltrating lymphocytes. J Gastroenterol Hepatol 2007; 22: 690-696.
67. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX and Wang FS. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339.
68. Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S and Shim H. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Bio-phys Res Commun 2007; 359: 716-722.
69. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB and Newcomb EW. Hypoxia-inducible factor 1 and VEGF up-regulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006; 86: 1221-1232.
70. Gupta A, Zhou CQ and Chellaiah MA. Osteo-pontin and MMP9: Associations with VEGF Expression/Secretion and Angiogenesis in PC3 Prostate Cancer Cells. Cancers 2013; 5: 617-638.
71. Li W, Gomez E and Zhang Z. Immunohisto-chemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J Exp Clin Cancer Res 2007; 26: 527-533.
72. Siegel AB, Cohen EI, Ocean A, Lehrer D, Gold-enberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafi S and Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-2998.
73. Zhu AX, Sahani DV, Duda DG, di Tomaso E, An-cukiewicz M, Catalano OA, Sindhwani V, Blasz-kowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP and Jain RK. Effcacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27: 3027-3035.
74. Matsusue R, Kubo H, Hisamori S, Okoshi K, Takagi H, Hida K, Nakano K, Itami A, Kawada K, Nagayama S and Sakai Y. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol 2009; 16: 2645-2653.
75. Xiang ZL, Zeng ZC, Fan J, Wu WZ, He J, Zeng HY and Tang ZY. A clinicopathological model to predict bone metastasis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2011; 137: 1791-1797.
76. Li N, Guo W, Shi J, Xue J, Hu H, Xie D, Wu M and Cheng S. Expression of the chemokine receptor CXCR4 in human hepatocellular carcinoma and its role in portal vein tumor thrombus. J Exp Clin Cancer Res 2010; 29: 156.
77. Costantini S, Raucci R, De Vero T, Castello G and Colonna G. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural li-gands, CXCL11 and CXCL12, by a modeling approach. Cytokine 2013; 64: 316-321.
78. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC and Schall TJ. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007; 104: 15735-15740.
79. Iwakiri S, Mino N, Takahashi T, Sonobe M, Nagai S, Okubo K, Wada H, Date H and Miya-hara R. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer 2009; 115: 2580-2593.
80. Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, Kaif JT, Sauter G, Izbicki JR and Bockhorn M. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J Surg Oncol 2011; 104: 140-145.
81. Deutsch AJ, Steinbauer E, Hofmann NA, Strunk D, Gerlza T, Beham-Schmid C, Schaider H and Neumeister P. Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregula-tion of CXCR7 is associated with progression to diffuse large B-cell lymphoma. Mod Pathol 2013; 26: 182-194.
82. Hou KL, Hao MG, Bo JJ and Wang JH. CXCR7 in tumorigenesis and progression. Chin J Cancer 2010; 29: 456-459.
83. Hattermann K, Held-Feindt J, Lucius R, Muerkoster SS, Penfold ME, Schall TJ and Mentlein R. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 2010; 70: 3299-3308.
84. Meijer J, Ogink J and Roos E. Effect of the che-mokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br J Cancer 2008; 99: 1493-1501.
85. Dai X, Tan Y, Cai S, Xiong X, Wang L, Ye Q, Yan X, Ma K and Cai L. The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells. J Cell Mol Med 2011; 15: 1299-1309.
86. Hao M, Zheng J, Hou K, Wang J, Chen X, Lu X, Bo J, Xu C and Shen K. Role of chemokine receptor CXCR7 in bladder cancer progression. Biochem Pharmacol 2012; 84: 204-214.
87. Sanchez-Alcaniz JA, Haege S, Mueller W, Pla R, Mackay F, Schulz S, Lopez-Bendito G, Stumm R and Marin O. Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron 2011; 69: 77-90.
88. Luker KE, Gupta M and Luker GD. Imaging che-mokine receptor dimerization with frefy lucif-erase complementation. FASEB J 2009; 23: 823-834.
89. Naumann U, Cameroni E, Pruenster M, Maha-baleshwar H, Raz E, Zerwes HG, Rot A and Thelen M. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One 2010; 5: e9175.
90. Decaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP and Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem 2011; 286: 32188-32197.
91. Singh S, Srivastava SK, Bhardwaj A, Owen LB and Singh AP. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer 2010; 103: 1671-1679.
92. Kumar R, Tripathi V, Ahmad M, Nath N, Mir RA, Chauhan SS and Luthra K. CXCR7 mediated Gialpha independent activation of ERK and Akt promotes cell survival and chemotaxis in T cells. Cell Immunol 2012; 272: 230-241.
93. Xue TC, Chen RX, Han D, Chen J, Xue Q, Gao DM, Sun RX, Tang ZY and Ye SL. Down-regulation of CXCR7 inhibits the growth and lung metastasis of human hepatocellular carcinoma cells with highly metastatic potential. Exp Ther Med 2012; 3: 117-123.
94. Zheng K, Li HY, Su XL, Wang XY, Tian T, Li F and Ren GS. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2010; 29: 31.
95. Xue TC, Chen RX, Ren ZG, Zou JH, Tang ZY and Ye SL. Transmembrane receptor CXCR7 increases the risk of extrahepatic metastasis of relatively well-differentiated hepatocellular carcinoma through upregulation of osteopon-tin. Oncol Rep 2013; 30: 105-110.
96. Monnier J, Boissan M, L'Helgoualc'h A, La-combe ML, Turlin B, Zucman-Rossi J, Theret N, Piquet-Pellorce C and Samson M. CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifcally expressed by en-dothelial cells. Eur J Cancer 2012; 48: 138-148.
97. Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG and Jain RK. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neu-ropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009; 69: 7905-7910.
98. Liu H, Xue W, Ge G, Luo X, Li Y, Xiang H, Ding X, Tian P and Tian X. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1alpha in MSCs. Biochem Biophys Res Commun 2010; 401: 509-515.